Lyell Immunopharma Inc. (NASDAQ:LYEL) remained unchanged to close Friday at $2.24 after subtracting $0.0 on the day. The 5-day average trading volume is 663,880 shares of the company’s common stock. It has gained $2.43 in the past week and touched a new high 1 time within the past 5 days. An average of 635,665 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 960,950.
LYEL’s 1-month performance is -27.74% or -$0.85 on its low of $2.16 reached on 08/15/23. The company’s shares have touched a 52-week low of $1.77 and high of $8.74, with the stock’s rally to the 52-week high happening on 06/16/23. YTD, LYEL has lost -35.45% or -$1.23 and has reached a new high 5 times. However, the current price is down -74.37% from the 52-week high price.
Insider Transactions
LYEL stock investors last saw insider trading activity on Aug 15.Klausner Richard (Director) most recently sold 58,020 shares at $2.28 per share on Aug 15. This transaction cost the insider $132,286. Director, Klausner Richard, sold 11,100 shares at a price of $6.40 on Sep 23.
Valuation Metrics
LYEL stock has a beta of -1.26. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 11.53 while the price-to-book (PB) in the most recent quarter is 0.76.
Lyell Immunopharma Inc.’s quick ratio for the period ended June 29 was 17.60, with the current ratio over the same period at 17.60. The trailing 12-month EBITDA margin is -207.06%. The firm’s gross profit as reported stood at $271.74 million against revenue of $84.68 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 43.15% to -$63.89 million, while revenue of -$66.96 million was -4.81% off the previous quarter. Analysts expected LYEL to announce -$0.27 per share in earnings in its latest quarter, but it posted -$0.18, representing a 33.30% surprise. EBITDA for the quarter stood at more than -$62.92 million. LYEL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 98.5 million, with total debt at $66.07 million. Shareholders hold equity totaling $251.03 million.
Let’s look briefly at Lyell Immunopharma Inc. (LYEL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 29.52% to suggest the stock is trending oversold, with historical volatility in this time period at 39.25%.
The stock’s 5-day moving average is $2.24, reflecting a -3.03% or -$0.07 change from its current price. LYEL is currently trading -30.43% above its 20-day SMA, +2.28% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -31.29% and SMA200 by-61.90%.
Stochastic %K and %D was 10.83% and 10.38% and the average true range (ATR) pointed at 0.17. The RSI (14) points at 34.01%, while the 14-day stochastic is at 10.96% with the period’s ATR at 0.18. The stock’s 9-day MACD Oscillator is pointing at -0.05 and -0.16 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Lyell Immunopharma Inc. (NASDAQ: LYEL), Morgan Stanley downgraded it to an Equal-weight rating. They previously had an Overweight rating on the stock. Analysts offering their rating for LYEL stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate LYEL as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is LYEL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $10.00, with their median price target at $9.00. Looking at these predictions, the average price target given by analysts is for Lyell Immunopharma Inc. (LYEL) stock is $8.33.
